Erasca, Inc. (ERAS)
Erasca is a San Diego company developing investigational cancer drugs that target the RAS/MAPK cell signaling pathway. It last closed at $13.89 on Nov 17, down 8.07% on the day. Over the past 90 days StreetAlpha recorded 2 whale options trades in ERAS, 50% of them bullish and 50% bearish. In the past 30 days there were 3 dark pool prints totaling $4.3M, the largest $3.4M.
Key Stats
Last 12 monthsNot reported for this period.
From ERAS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 1 analyst who set a price target on ERAS in the past 90 days. The average target is $35.00, with a high of $35.00 and a low of $35.00, compared with the last close of $13.89.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 17 | Leerink Partners | Initiated | Buy | $35 |
| Aug 14 | B of A Securities | Target raised | Hold | $18 → $20 |
| Aug 13 | Guggenheim | Maintained | Buy | $21 |
| Aug 12 | HC Wainwright & Co. | Maintained | Buy | $22 |
| Jul 20 | Morgan Stanley | Maintained | Hold | $21 |
Technical Analysis
The stock is 7% below its 20 day and 7% below its 50 day average. It is 10% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 44). The nearest support is the swing low (Oct 8) at $13.78, and the nearest resistance the Pivot at $14.39.
| RSI (14) | 43.61 | Middle of its range | Neutral |
| MACD | 0.05 | Above its signal line | Bullish |
| Stochastic | 42.0 | Middle of its range | Neutral |
| ADX (14) | 11.0 | No clear trend | |
| Williams %R | -81.6 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -58.7 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −5.1% | Change over 10 sessions | Bearish |
| ATR (14) | $1.26 | Typical daily range, 9.1% of price |
| RSI (14) | 46.42 | Middle of its range | Neutral |
| MACD | 0.08 | Below its signal line | Bearish |
| Stochastic | 21.3 | Middle of its range | Neutral |
| ADX (14) | 23.6 | Weak trend | |
| Williams %R | -89.2 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -76.6 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −12.5% | Change over 10 sessions | Bearish |
| ATR (14) | $2.34 | Typical daily range, 16.9% of price |
What happened before
See how ERAS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ERAS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in ERAS in the last 90 days.
Dark Pool
30DERAS Institutional Ownership
Full report →- ▲177 buying vs 95 selling
- ▲Held by funds +13.0 pts
- ▲Funds holding +14
- ▲Superinvestors: 3 added, 2 cut
- ▼Put/call 0.13 to 0.23
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 273 | 259 | +5.4% |
| In funds' top 10 | 13 | 14 | −7.1% |
| Held by funds | 93.3% | 80.2% | +13.0 pts |
| New / increased | 43 / 134 | 62 / 101 | +8.6% |
| Reduced / sold out | 65 / 30 | 76 / 28 | −8.7% |
| Put/call ratio | 0.23 | 0.13 | +81.5% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ERAS is in one of them and how their past ERAS trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ERAS in an article yet. Here's the latest on the wider market.
ERAS Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Scott A KuporExecutive branch | Sell | $1K – $15K | Jul 30, 2026 | Sep 30, 2026 | 62 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Erasca
Erasca is a biopharmaceutical company based in San Diego, California, that develops cancer treatments. Its work focuses on tumors driven by changes in the RAS/MAPK pathway, a cell signaling pathway that many cancers rely on. The company's pipeline includes investigational drugs that target RAS and other points in the pathway, given alone or in combination, aimed at patients whose cancers have few targeted treatment options. These candidates are still in clinical testing and are not yet approved for sale.
- Headquarters
- San Diego, CA





